Drugs / NKT5097
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07029399 | Mar 2025 → Jul 2027 expected | hormone receptor-positive breast cancer, triple-negative breast carcinoma | NiKang Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NKT5097 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07029399 ↗ |
| Route | Oral | “Escalation of orally administered NKT5097” NCT07029399 ↗ |
| Target | CDK2 | “a novel dual protein degrader of CDK2 and CDK4” NCT07029399 ↗ |
| Target | CDK4 | “a novel dual protein degrader of CDK2 and CDK4” NCT07029399 ↗ |